The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo-Reference-Cited by-同舟云学术

The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo

Published:2023-10 Issue: Volume:196 Page:106926
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Pang Yuheng,Shi Runze,Chan Liujia,Lu Yu,Zhu Di,Liu Tong,Yan Meisi,Wang Yuji,Wang Wenjing

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Pharmacology

Reference35 articles.

1. The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials;Huynh;Expert Opin. Invest. Drugs,2020

2. A longitudinal study of diurnal cortisol patterns and associated factors in breast cancer patients from the transition stage of the end of active cancer treatment to post-treatment survivorship;Hsiao;Breast,2017

3. Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance;Al-Malky;J. Oncol. Pharm. Pr.,2020

4. Doxorubicin-resistant TNBC cells exhibit rapid growth with cancer stem cell-like properties and EMT phenotype, which can be transferred to parental cells through autocrine signaling;Paramanantham;Int. J. Mol. Sci.,2021

5. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066;Cheng;Int. J. Oncol.,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BET degrader exhibits lower antiproliferative activity than its inhibitor via EGR1 recruiting septins to promote E2F1-3 transcription in triple-negative breast cancer;Pharmacological Research;2024-10

2. Caffeic acid inhibits the tumorigenicity of triple-negative breast cancer cells through the FOXO1/FIS pathway;Biomedicine & Pharmacotherapy;2024-09

3. Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer;Current Pharmaceutical Biotechnology;2024-07-31

4. Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma;Frontiers in Immunology;2024-06-12